Related Experiment Videos
A personal perspective on the treatment of heart failure in 1994
1University of California, San Francisco.
Insights
Standard triple therapy is recommended for most heart failure patients, but managing persistent symptoms and related issues like arrhythmias remains challenging. This review details a 1994 approach to left ventricular systolic dysfunction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure treatment has significantly advanced in recent decades.
- Angiotensin-converting enzyme inhibitors are now standard for symptomatic and asymptomatic left ventricular dysfunction.
Purpose of the Study:
- To outline a 1994 approach to managing patients with left ventricular systolic dysfunction.
- To discuss standard triple therapy and challenges in heart failure management.
Main Methods:
- Review of current (1994) treatment strategies for heart failure.
- Discussion of pharmacologic interventions including ACE inhibitors, diuretics, and digoxin.
- Consideration of managing persistent symptoms, arrhythmias, and thromboembolic risk.
Main Results:
- Angiotensin-converting enzyme inhibitors are standard therapy.
- Diuretic regimens are potent and sophisticated.
- Digoxin's role in survival remains uncertain, but its efficacy is clearer.
Conclusions:
- Most symptomatic patients benefit from standard triple therapy.
- Managing patients refractory to triple therapy requires further consideration.
- Addressing arrhythmias and thromboembolic risk is crucial in heart failure management.
Abstract:
The treatment of heart failure has advanced greatly over the past two decades. Angiotensin-converting enzyme inhibitors have become standard therapy, not only in symptomatic patients but also in those with asymptomatic left ventricular dysfunction. Diuretic regimens have become increasingly potent and sophisticated. Much of the controversy over the efficacy of digoxin has been resolved, although its effect on survival is still uncertain. Most symptomatic patients, therefore, should be treated with what has become "standard" triple therapy, but practices vary as to when and at what dose to use these medications. More problematic is how to treat the patient who remains symptomatic on a three-drug regimen, and how to manage ancillary but important issues such as arrhythmias and thromboembolic risk. This article reflects the author's personal approach to managing the patient with left ventricular systolic dysfunction in 1994.